Virogenomics Inc, spun off from research done at Oregon Health & Science University, is using gene-based automation in the discovery and validation of novel drug targets and the development of new drugs for the treatment of human disease. Also dba Virogenomic Biodevelopment, the firm is working to develop technologies from OHSU in the areas of cancer, stroke, cardiovascular disease and antiviral diseases. The firm is privately held and uses a business strategy of identifying and obtaining rights to early-stage technologies, then managing and developing these technologies to a critical phase before spinning off the developed technologies into new start-up companies. Virogenomics has obtained rights to technologies in three general disease areas including autoimmune diseases, stroke, and infectious diseases. The autoimmune technology was spun-off in 2004 into a subsidiary named Artielle ImmunoTherapeutics; The stroke technology was spun off into its own entity, NeuroProtect Inc; the firm also created I D Biopharma via a consolidation of infectious disease technologies from Virogenomics and OHSU.